--- title: Early-Phase Development & Manufacturing CDMO | Siegfried description: Accelerate early-phase drug development with integrated CDMO services for process development, analytical testing, GMP manufacturing, and clinical supply. --- This is a search field with an auto-suggest feature attached. - There are no suggestions because the search field is empty. - [Careers](https://www.siegfried.ch/careers/) - [Media](https://www.siegfried.ch/media/) - [Investors](https://www.siegfried.ch/investors/) - [Contact us](https://www.siegfried.ch/contact/) [Company](https://www.siegfried.ch/company/) Company [Purpose](https://www.siegfried.ch/company/purpose/) [Strategy](https://www.siegfried.ch/company/strategy/) [Leadership](https://www.siegfried.ch/company/leadership/) [History](https://www.siegfried.ch/company/history/) [Locations](https://www.siegfried.ch/company/locations/) [Offering](https://www.siegfried.ch/offering/) Offering [Drug Substances](https://www.siegfried.ch/offering/drug-substances/) [Exclusive synthesis](https://www.siegfried.ch/offering/drug-substances/exclusive-synthesis/) [API portfolio](https://www.siegfried.ch/offering/drug-substances/api/) [Reference standards](https://www.siegfried.ch/reference-standards/) [Preclinical and early-phase development](https://content.siegfried.ch/siegfried-acceleration-hub?hsLang=en) [Alkaloid raw materials extraction](https://extractas.com.au/) [Drug Products](https://www.siegfried.ch/offering/drug-products/) [Oral solid dosage forms](https://www.siegfried.ch/offering/drug-products/oral-solids/) [Sterile injectables](https://www.siegfried.ch/offering/drug-products/sterile-injectables/) [Ophthalmics](https://www.siegfried.ch/offering/drug-products/ophthalmics/) [Inhalation products](https://www.siegfried.ch/offering/drug-products/inhalatives/) [Viral vectors](https://dinamiqs.com/) [Technologies](https://www.siegfried.ch/technologies/) [Sustainability](https://www.siegfried.ch/sustainability/) Sustainability [People](https://www.siegfried.ch/sustainability/people/) [Environment](https://www.siegfried.ch/sustainability/environment/environment/) [Integrity](https://www.siegfried.ch/sustainability/integrity/) [Quality](https://www.siegfried.ch/sustainability/quality/) [Community engagement](https://siegfried.ch/sustainability/community-engagement/) [Risk management](https://www.siegfried.ch/sustainability/risk-management/) [Insights](https://content.siegfried.ch/insights?hsLang=en) [![](https://content.siegfried.ch/hubfs/siegfried-logo.svg)](https://www.siegfried.ch/) What are you looking for? [![](https://content.siegfried.ch/hubfs/siegfried-logo.svg)](https://www.siegfried.ch/) [Company](https://www.siegfried.ch/company/) [Purpose](https://www.siegfried.ch/company/purpose/) [Strategy](https://www.siegfried.ch/company/strategy/) [Leadership](https://www.siegfried.ch/company/leadership/) [History](https://www.siegfried.ch/company/history/) [Locations](https://www.siegfried.ch/company/locations/) [Offering](https://www.siegfried.ch/offering/) [Drug Substances](https://www.siegfried.ch/offering/drug-substances/) [Exclusive synthesis](https://www.siegfried.ch/offering/drug-substances/exclusive-synthesis/) [API portfolio](https://www.siegfried.ch/offering/drug-substances/api/) [Reference standards](https://www.siegfried.ch/reference-standards/) [Preclinical and early-phase development](https://content.siegfried.ch/siegfried-acceleration-hub?hsLang=en) [Alkaloid raw materials extraction](https://extractas.com.au/) [Drug Products](https://www.siegfried.ch/offering/drug-products/) [Oral solid dosage forms](https://www.siegfried.ch/offering/drug-products/oral-solids/) [Sterile injectables](https://www.siegfried.ch/offering/drug-products/sterile-injectables/) [Ophthalmics](https://www.siegfried.ch/offering/drug-products/ophthalmics/) [Inhalation products](https://www.siegfried.ch/offering/drug-products/inhalatives/) [Viral vectors](https://dinamiqs.com/) [Technologies](https://www.siegfried.ch/technologies/) [Sustainability](https://www.siegfried.ch/sustainability/) [People](https://www.siegfried.ch/sustainability/people/) [Environment](https://www.siegfried.ch/sustainability/environment/environment/) [Integrity](https://www.siegfried.ch/sustainability/integrity/) [Quality](https://www.siegfried.ch/sustainability/quality/) [Community engagement](https://siegfried.ch/sustainability/community-engagement/) [Risk management](https://www.siegfried.ch/sustainability/risk-management/) [Insights](https://content.siegfried.ch/insights?hsLang=en) - [Careers](https://www.siegfried.ch/careers/) - [Media](https://www.siegfried.ch/media/) - [Investors](https://www.siegfried.ch/investors/) - [Contact us](https://www.siegfried.ch/contact/) [Offering](https://www.siegfried.ch/offering/) / [Siegfried
Acceleration Hub](https://content.siegfried.ch/siegfried-acceleration-hub?hsLang=en) / [Early-phase development and manufacturing](https://content.siegfried.ch/early-phase-development-and-manufacturing) # Early-phase development and manufacturing services At Acceleration Hub, we work with emerging biotech companies and large pharma partners, combining route selection, process development, analytical capabilities, and manufacturing into one coordinated approach - including expertise in highly potent APIs and controlled substances.  With experienced teams, established processes, and dedicated infrastructure, we enable efficient project progression under tight timelines and evolving requirements. [Get in touch](https://content.siegfried.ch/early-phase-development-and-manufacturing#bottom-form) ![bild](https://content.siegfried.ch/hs-fs/hubfs/bild.webp?width=606&height=410&name=bild.webp) ## From concept to clinical supply ![Siegfried-process-development-icon-navy](https://content.siegfried.ch/hubfs/Siegfried-process-development-icon-navy.svg) ### Process 
 development The Acceleration Hub applies phase-appropriate process development from early development through GMP manufacturing, supporting efficient progression from initial routes to robust manufacturing processes. Our teams focus on translating medicinal chemistry into scalable, reliable processes, using a structured approach that integrates process understanding, quality-by-design principles, and data-driven development. Broad experience across molecular scaffolds enables efficient development of new chemical entities and APIs, with a clear focus on scalability and transfer into manufacturing.   ![Siegfried-zoom-icon-navy-new](https://content.siegfried.ch/hubfs/Siegfried-zoom-icon-navy-new.svg) ### Analytical 
 capabilities  The Acceleration Hub offers comprehensive in-house analytical capabilities, including ICH-compliant stability studies and full support for controlled substances. Services include phase-appropriate analytical method development, validation and transfer, impurity identification, preformulation studies, and release and stability testing, aligned with regulatory requirements. - Mass spectroscopy - Nuclear magnetic spectroscopy - Physical property characterization - Liquid Chromatography - Gas Chromatography - Wet Chemistry tests - Full-spectrum ICH stability studies ![Icon\_Check\_32pc](https://content.siegfried.ch/hubfs/Icon_Check_32pc.svg) ### Regulatory support from development to approval The Acceleration Hub provides regulatory expertise across all development stages, supporting global filings from early development through commercial approval. Capabilities include CMC documentation, compliance with international regulatory requirements, and support for submissions to major health authorities, ensuring efficient and reliable progression through regulatory milestones. ## Insights from our experts ![20230424\_Siegfried\_Barcelona18855-gigapixel-standard-scale-2\_00x-1](https://content.siegfried.ch/hs-fs/hubfs/20230424_Siegfried_Barcelona18855-gigapixel-standard-scale-2_00x-1.jpg?width=2000&name=20230424_Siegfried_Barcelona18855-gigapixel-standard-scale-2_00x-1.jpg) ### Three success factors to accelerate your program to clinical trial Read article ![20230424\_Siegfried\_Barcelona18803\_300ppi\_RGB\_RZ (1)](https://content.siegfried.ch/hs-fs/hubfs/20230424_Siegfried_Barcelona18803_300ppi_RGB_RZ%20(1).jpg?width=2000&name=20230424_Siegfried_Barcelona18803_300ppi_RGB_RZ%20(1).jpg) ### Ask better, move faster: Questions that will accelerate the speed of your program to clinical Read article Subscribe now to get more expert insights   Subscribe ## Get in touch with us expect more **Siegfried AG** Untere Brühlstrasse 4 4800 Zofingen, Switzerland [+41 62 746 11 11](tel:+41627461111) [Get in touch](https://www.siegfried.ch/contact-us/) #### About us - [Our company](https://www.siegfried.ch/company/) - [Sustainability](https://www.siegfried.ch/sustainability/) - [Media](https://www.siegfried.ch/media/) - [Investors](https://www.siegfried.ch/investors/) - [Careers](https://www.siegfried.ch/careers/) #### Helpful resources - [Expert insights](https://content.siegfried.ch/insights?hsLang=en) - [News archive](https://www.siegfried.ch/news-archive/) - [Reports](https://www.siegfried.ch/investors/investors-download-center-2025/) - [Terms and conditions](https://www.siegfried.ch/terms-and-conditions/) #### Offering - [Drug Substances](https://www.siegfried.ch/offering/drug-substances/) - [Drug Products](https://www.siegfried.ch/offering/drug-products/) - [Technologies](https://www.siegfried.ch/technologies/) 2026 © Siegfried Holding AG - [Privacy Policy](https://www.siegfried.ch/privacy-policy/) - [Legal disclaimer](https://www.siegfried.ch/legal-disclaimer/) - [Imprint](https://www.siegfried.ch/imprint/)